Davis Polk is advising J.P. Morgan Securities as financial adviser to Medivation, Inc. in connection with its approximately $14 billion acquisition by Pfizer Inc. The acquisition, which is expected to close in the third or fourth quarter of 2016, is subject to customary closing conditions, including U.S. antitrust clearance and the tender of a majority of the outstanding shares of Medivation common stock.

Medivation is a biopharmaceutical company focused on the development and commercialization of medically innovative therapies to treat serious diseases for which there are limited treatment options. Pfizer applies science and its global resources to bring therapies to people that extend and significantly improve their lives.

The Davis Polk corporate team includes partner Alan F. Denenberg and associate Max Brunner. All members of the Davis Polk team are based in the Northern California office.

Copy link to share post